First Domestic GLP-1 Obesity Drug Released… Hanmi Pharmaceutical’s 'Epe' Receives Approval
5 Articles
5 Articles
Korea's first glucagon-like peptide (GLP-1, GLP-1) obesity treatment similar to WeGo Bee and Mounjaro is being released. The Ministry of Food and Drug Safety announced on the 7th that it has approved the new drug “EPE autoinjector” (efeglenide) developed by Hanmi Pharmaceuticals. The approved dosage is 2, 4, 6, 8, and 10 mg.
A new domestic obesity drug has been launched. The Ministry of Food and Drug Safety announced on the 7th that it has approved Hanmi Pharmaceutical's EFE as the 45th new drug. EFE is available in dosages of 2 mg, 4 mg, 6 mg, 8 mg, and 10 mg. Like Wigobi and Maunzaro, EFE is a drug that mimics the glucagon-like peptide (GLP)-1 hormone secreted from the intestines after a meal. Its principle is to induce a feeling of fullness by suppressing appetit…
(Seoul = Yonhap News) Reporter Park Sang-hyun = The Ministry of Food and Drug Safety [128940]'s glucagon-like peptide-1 (GLP-1) class obesity treatment drug '...
45th Domestic New Drug Draws Attention... Establishing Position in the Two-Way Dominance of Maunzaro and Wigovi
The Ministry of Food and Drug Safety has approved the first domestically developed glucagon-like peptide-1 (GLP-1) class obesity treatment.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
